Proactive Investors - Run By Investors For Investors

NetScientific’s Glycotest subsidiary allowed Chinese patent for liver cancer blood test

Having IP protection for HCC Panel in China is an important milestone for Glycotest, with the country having a notoriously high liver cancer death rate
liver
NetScientific holds an 87.5% stake in Glycotest, or 67% on a fully diluted basis

Glycotest, a portfolio company of Netscientific PLC (LON:NSCI), has been allowed a patent in China for its lead product, HCC Panel – a blood test designed to detect early-stage liver cancer.

The patent expands the company's existing patent portfolio, which stands at ten previously granted or allowed patents, protecting multiple aspects of its proprietary liver disease diagnostic platform.

READ: NetScientific's Glycotest subsidiary granted Japanese patent

Having IP protection for HCC Panel in China is an important milestone for Glycotest, with the country having a notoriously high liver cancer death rate.

Glycotest also holds patents in the US, Europe, Japan and Australia covering the use of over 50 unique glycoprotein biomarkers and related assay technology for the diagnosis of liver cancers and other liver diseases.

In two studies, HCC Panel has shown that it has the potential to outperform the current dominant blood test regarding the early detection of liver cancer in patients with cirrhosis.

READ: NetScientific positioned for continued commercial momentum

NetScientific holds an 87.5% stake in Glycotest, or 67% on a fully diluted basis.

"We are pleased to announce that Glycotest's IP portfolio will now also cover China, a highly significant market, which accounts for over 50% of worldwide deaths from liver cancer. We believe Glycotest's HCC panel will enable early detection of HCC and, once commercialised, will change the paradigm of care."

NetScientific shares jumped 2.8% to 56p early on Thursday.

View full NSCI profile View Profile

Netscientific PLC Timeline

Related Articles

researcher filling a tray of samples
December 14 2018
The company has two clinical trials underway and is well funded to achieve its immediate ambitions
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use